Aptose Biosciences Files 8-K on Financials
Ticker: APTOF · Form: 8-K · Filed: Mar 28, 2025 · CIK: 882361
Sentiment: neutral
Topics: financial-condition, exhibits, company-update
TL;DR
Aptose Biosciences dropped an 8-K detailing its financial condition and exhibits.
AI Summary
Aptose Biosciences Inc. filed an 8-K on March 28, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is based in Toronto, Canada, and operates in the biological products sector.
Why It Matters
This filing provides investors with an update on Aptose Biosciences' financial health and operational status, which is crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain information about significant new risks or events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc. (company) — Former company name
- March 28, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Aptose Biosciences Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 28, 2025.
What are the former names of Aptose Biosciences Inc.?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
Where is Aptose Biosciences Inc. headquartered?
Aptose Biosciences Inc. is headquartered in Toronto, Canada.
What is the Standard Industrial Classification (SIC) code for Aptose Biosciences Inc.?
The SIC code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding Aptose Biosciences Inc. (APTOF).